More recently, OBP-702 was shown to promote the therapeutic potential of PD-L1 blockade against murine pancreatic cancer tumors by suppressing the tumor accumulation of immunosuppressive myeloid-derived suppressor cells.44 This evidence concerns the gene CD274 and pancreatic neoplasm.